Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.
D'Angelo S, Tirri E, Giardino AM, Mattucci-Cerinic M, Dagna L, Santo L, Ciccia F, Frediani B, Govoni M, Bobbio Pallavicini F, Grembiale RD, Delle Sedie A, Mulè R, Cantatore FP, Foti R, Gremese E, Conigliaro P, Salaffi F, Viapiana O, Cauli A, Giacomelli R, Arcarese L, Guggino G, Russo R, Puenpatom A, Capocotta D, Nacci F, Anelli MG, Picerno V, Binetti C, Iannone F.
D'Angelo S, et al.
J Clin Med. 2022 Jul 19;11(14):4178. doi: 10.3390/jcm11144178.
J Clin Med. 2022.
PMID: 35887946
Free PMC article.
The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were also assessed. A total of 194 patients aged 53.2 12 years started GLM as a second anti-TNF drug: 39 (20.1%) with RA, 91 (46.9%) with PsA and 64 …
The primary objective was to evaluate the effectiveness of GLM after 6 months. Changes in quality of life using the EQ-5D-5L were als …